Have we fallen off target with concerns surrounding dual RAAS blockade

Kidney International

Volumn 78, Issue 6, 2010, Pages 539-545

  Lattanzio, Michael R ^a   Weir, Matthew R ^a  

^a UNIVERSITY OF MARYLAND SCHOOL OF MEDICINE   (United States)

Author keywords

cardiovascular disease; chronic kidney disease; proteinuria; RAAS blockade

Indexed keywords

ALISKIREN; ANGIOTENSIN RECEPTOR ANTAGONIST; CANDESARTAN; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; ENALAPRIL; EPLERENONE; LOSARTAN; MINERALOCORTICOID ANTAGONIST; RAMIPRIL; SPIRONOLACTONE; TELMISARTAN;

ACUTE HEART INFARCTION; ALBUMINURIA; CHRONIC KIDNEY DISEASE; CLINICAL TRIAL; CONGESTIVE HEART FAILURE; DRUG EFFICACY; DRUG SAFETY; ESSENTIAL HYPERTENSION; HEART LEFT VENTRICLE HYPERTROPHY; HEART PROTECTION; HUMAN; PRIORITY JOURNAL; PROTEINURIA; RENAL PROTECTION; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; SHORT SURVEY;

EID: 77956231922     PISSN: 00852538     EISSN: 15231755     Source Type: Journal    
DOI: 10.1038/ki.2010.225     Document Type: Short Survey

References (33)

1. Yusuf S, Teo KK, Pogue J et al. Telmisartan, ramipril, or both in patients at high risk for vascular events. N Engl J Med 2008; 358: 1547-1559.
2. Klahr S, Levey AS, Beck GJ et al. The effects of dietary protein restriction and blood-pressure control on the progression of chronic renal disease. Modification of Diet in Renal Disease Study Group. N Engl J Med 1994; 330: 877-884.
3. Palmer BF. Renal dysfunction complicating the treatment of hypertension. N Engl J Med 2002; 347: 1256-1261.
4. Lindeman RD, Tobin J, Shock NW. Longitudinal studies on the rate of decline in renal function with age. J Am Geriatr Soc 1985; 33: 278-285.
5. Mann JF, Schmieder RE, McQueen M et al. Renal outcomes with telmisartan, ramipril, or both, in people at high vascular risk (the ONTARGET study): a multicentre, randomised, double-blind, controlled trial. Lancet 2008; 372: 547-553.
6. Stel VS, Jager KJ, Zoccali C et al. The randomized clinical trial: an unbeatable standard in clinical research? Kidney Int 2007; 72: 539-542.
7. Messerli FH. The sudden demise of dual renin-angiotensin system blockade or the soft science of the surrogate end point. J Am Coll Cardiol 2009; 53: 468-470.
8. Weir M, Rolfe M. Potassium homeostasis and renin-angiotensin-aldosterone system inhibitors. Clin J Am Soc Nephrol 2010; 5: 531-548.
9. Parving HH, Brenner BM, McMurray JJ et al. Aliskiren Trial in Type 2 Diabetes Using Cardio-Renal Endpoints (ALTITUDE): rationale and study design. Nephrol Dial Transplant 2009; 24: 1663-1671.
10. Fried LF, Duckworth W, Zhang JH et al. Design of combination angiotensin receptor blocker and angiotensin-converting enzyme inhibitor for treatment of diabetic nephropathy (VA NEPHRON-D). Clin J Am Soc Nephrol 2009; 4: 361-368.
11. De Zeeuw D, Remuzzi G, Parving HH et al. Proteinuria a target for renoprotection in patients with type 2 diabetic nephropathy: lessons from RENAAL. Kidney Int 2004; 65: 2309-2320.
12. De Zeeuw D, Remuzzi G, Parving HH et al. Albuminuria a therapeutic target for cardiovascular protection in type 2 diabetic patients with nephropathy. Circulation 2004; 110: 921-927.
13. Mann JF, Gerstein HC, Pogue J et al. Renal insufficiency as a predictor of cardiovascular outcomes and the impact of ramipril: the HOPE randomized trial. Ann Intern Med 2001; 134: 629-636.
14. Ibsen H, Olsen MH, Wachtell K et al. Reduction in albuminuria translates to reduction in cardiovascular events in hypertensive patients: losartan intervention for endpoint reduction in hypertension study. Hypertension 2005; 45: 198-202.
15. Eijkelkamp WB, Zhang Z, Remuzzi G et al. Albuminuria is a target for renoprotective therapy independent from blood pressure in patients with type 2 diabetic nephropathy: post hoc analysis from the Reduction of Endpoints in NIDDM with the Angiotensin II Antagonist Losartan (RENAAL) trial. J Am Soc Nephrol 2007; 18: 1540-1546.
16. Anavekar NS, Gans DJ, Berl T et al. Predictors of cardiovascular events in patients with type 2 diabetic nephropathy and hypertension: a case for albuminuria. Kidney Int Suppl 2004; 92: 550-555.
17. Norris KC, Greene T, Kopple J et al. Baseline predictors of renal disease progression in the African American Study of Hypertension and Kidney Disease. J Am Soc Nephrol 2006; 17: 2928-2936.
18. Atkins RC, Briganti EM, Lewis JB et al. Proteinuria reduction and progression to renal failure in patients with type 2 diabetes mellitus and overt nephropathy. Am J Kidney Dis 2005; 45: 281-287.
19. Peterson JC, Adler S, Burkart JM et al. Blood pressure control, proteinuria, and the progression of renal disease. The Modification of Diet in Renal Disease Study. Ann Intern Med 1995; 123: 754-762.
20. Kunz R, Friedrich C, Wolbers M et al. Meta-analysis: effect of monotherapy and combination therapy with inhibitors of the renin angiotensin system on proteinuria in renal disease. Ann Intern Med 2008; 148: 30-48.
21. Sengul AM, Altuntas Y, Kurklu A et al. Beneficial effect of lisinopril plus telmisartan in patients with type 2 diabetes, microalbuminuria and hypertension. Diabetes Res Clin Pract 2006; 71: 210-219.
22. Parving HH, Persson F, Lewis JB et al. Aliskiren combined with losartan in type 2 diabetes and nephropathy. N Engl J Med 2008; 358: 2433-2446.
23. Jennings DL, Kalus JS, Coleman CI et al. Combination therapy with an ACE inhibitor and an angiotensin receptor blocker for diabetic nephropathy: a meta-analysis. Diabet Med 2007; 24: 486-493.
24. Rossing K, Schjoedt KJ, Smidt UM et al. Beneficial effects of adding spironolactone to recommended antihypertensive treatment in diabetic nephropathy: a randomized, double-masked, cross-over study. Diabetes Care 2005; 28: 2106-2112.
25. Park S, Bivona BJ, Kobori H et al. Major role for ACE-independent intrarenal II ANG formation in type II diabetes. Am J Physiol Renal Physiol 2010; 298: F37-F48.
26. McMurray JJ, Ostergren J, Swedberg K et al. Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function taking angiotensin-converting-enzyme inhibitors: the CHARM-added trial. Lancet 2003; 362: 767-771.
27. Hamroff G, Katz SD, Mancini D et al. Addition of angiotensin II receptor blockade to maximal angiotensin-converting enzyme inhibition improves exercise capacity in patients with severe congestive heart failure. Circulation 1999; 99: 990-992.
28. Pitt B, Zannad F, Remme WJ et al. The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators. N Engl J Med 1999; 341: 709-717.
29. Pitt B, Remme W, Zannad F et al. Eplerenone a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction. N Engl J Med 2003; 348: 1309-1321.
30. Epstein M, Williams GH, Weinberger M et al. Selective aldosterone blockade with eplerenone reduces albuminuria in patients with type 2 diabetes. Clin J Am Soc Nephrol 2006; 1: 940-951.
31. Bomback AS, Kshirsagar AV, Amamoo MA et al. Change in proteinuria after adding aldosterone blockers to ACE inhibitors or angiotensin receptor blockers in CKD: a systematic review. Am J Kidney Dis 2008; 51: 199-211.
32. Krum H, Nolly H, Workman D et al. Efficacy of eplerenone added to renin-angiotensin blockade in hypertensive patients. Hypertension 2002; 40: 117-123.
33. Pitt B, Reichek N, Willenbrock R et al. Effects of eplerenone, enalapril, and eplerenone/enalapril in patients with essential hypertension and left ventricular hypertrophy: the 4E-left ventricular hypertrophy study. Circulation 2003; 108: 1831-1838.